The purpose of this study is to create models out of tissue samples and treat those models with the same immunotherapy treatment the patient will be receiving, in order to validate this process and to predict responses to therapies and use it to choose the best treatments for people in the future. The researchers will then examine the direct effects of the treatment on those models.
Study Type
OBSERVATIONAL
Enrollment
1
Organoid samples will be collected at time of biopsy and cultured in the lab. The samples will then receive the same standard of care immunotherapy treatment as the patient.
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, United States
Calculate overall patient response rate
Compare patient response using RECIST 1.1 criteria and immune-organoid response based on the following criteria: 1. Complete response \<50% of viable tumor cells 2. Response \>50%\<70% of viable tumor cells 3. Stable \>70%\<90% viable tumor cell left 4. Progressive \>90% of viable tumor cell left
Time frame: Baseline to 12 months
Reliability of organoid development
calculate the percentage of biopsies with successful organoid development
Time frame: Baseline to 2 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.